摘要
目的:本研究的目的是研究先兆子痫患者的血浆晚期糖基化产物(AGEs)血浆水平与代谢状况之间的关系,这是由于这些分子与氧化应激和炎症之间存在已知的关系,进而与PE的发病机制有关。 背景:据报道,与健康孕妇相比,先兆子痫患者的AGEs水平升高,这主要与氧化应激和炎症有关。此外,在患有先兆子痫的妇女中,存在代谢变化,例如高胰岛素血症,葡萄糖耐受不良,血脂异常,这些与胰岛素抵抗加剧有关。另外,一些参数指示肝功能的改变,例如肝酶水平的增加。但是,尚未评估先兆子痫中AGEs水平与脂,肝和葡萄糖代谢参数改变之间的关系。目的:探讨子痫前期妇女血浆血浆AGEs水平与肝,脂质和代谢谱的关系。 方法:通过竞争性酶联免疫吸附测定法(ELISA)测定15例先兆子痫患者和28例正常妊娠孕妇(对照组)的血浆AGEs水平。肝(血清肌酐,γ-谷氨酰转肽酶,天冬氨酸转氨酶,丙氨酸转氨酶,尿酸和乳酸脱氢酶),脂质(载脂蛋白A,载脂蛋白B,总胆固醇,甘油三酸酯,低密度脂蛋白,高密度脂蛋白和代谢变量),(葡萄糖,胰岛素和胰岛素抵抗)进行了评估。 结果:先兆子痫患者的血浆血浆AGEs水平明显高于对照组。在子痫前期患者中发现AGEs的循环水平与γ-谷氨酰转肽酶,尿酸,葡萄糖,胰岛素和HOMA-IR水平呈正相关。总之,先兆子痫患者的AGEs循环水平高于健康孕妇。此外,先兆子痫患者的肝脏和代谢状况变量,特别是与胰岛素抵抗相关的变量,比健康的孕妇要高。有趣的是,AGEs水平与胰岛素抵抗之间存在正相关。 结论:先兆子痫患者的AGEs循环水平高于健康孕妇。此外,先兆子痫的肝脏和代谢特征,特别是与胰岛素抵抗有关的特征,比健康怀孕的受试者要高。有趣的是,AGEs水平与胰岛素抵抗之间存在正相关关系,这表明糖基化过多和代谢状况受损会导致先兆子痫的生理病理。
关键词: 先兆子痫,晚期糖基化终产物,肝酶,尿酸,葡萄糖,胰岛素抵抗。
Current Molecular Medicine
Title:High Plasmatic Levels of Advanced Glycation End Products are Associated with Metabolic Alterations and Insulin Resistance in Preeclamptic Women
Volume: 20 Issue: 9
关键词: 先兆子痫,晚期糖基化终产物,肝酶,尿酸,葡萄糖,胰岛素抵抗。
摘要:
Aims: The purpose of this study was to investigate the association between plasmatic levels of advanced end glycation products (AGEs) and the metabolic profile in subjects diagnosed with preeclampsia, due to the known relation of these molecules with oxidative stress and inflammation, which in turn are related with PE pathogenesis.
Background: It has been reported that increased levels of AGEs are observed in patients with preeclampsia as compared with healthy pregnant subjects, which was mainly associated with oxidative stress and inflammation. Besides, in women with preeclampsia, there are metabolic changes such as hyperinsulinemia, glucose intolerance, dyslipidemia, among others, that are associated with an exacerbated insulin resistance. Additionally, some parameters indicate the alteration of hepatic function, such as increased levels of liver enzymes. However, the relationship of levels of AGEs with altered lipidic, hepatic, and glucose metabolism parameters in preeclampsia has not been evaluated.
Objective: To investigate the association between plasmatic levels of AGEs and hepatic, lipid, and metabolic profiles in women diagnosed with preeclampsia.
Methods: Plasma levels of AGEs were determined by a competitive enzyme-linked immunosorbent assay (ELISA) in 15 patients diagnosed with preeclampsia and 28 normoevolutive pregnant subjects (control group). Hepatic (serum creatinine, gammaglutamyl transpeptidase, aspartate transaminase, alanine transaminase, uric acid, and lactate dehydrogenase), lipid (apolipoprotein A, apolipoprotein B, total cholesterol, triglycerides, low-density lipoproteins, and high-density lipoproteins), and metabolic variables (glucose, insulin, and insulin resistance) were assessed.
Results: Plasmatic levels of AGEs were significantly higher in patients with preeclampsia as compared with the control. A positive correlation between circulating levels of AGEs and gamma-glutamyl transpeptidase, uric acid, glucose, insulin, and HOMA-IR levels was found in patients with preeclampsia. In conclusion, circulating levels of AGEs were higher in patients with preeclampsia than those observed in healthy pregnant subjects. Besides, variables of hepatic and metabolic profile, particularly those related to insulin resistance, were higher in preeclampsia as compared with healthy pregnant subjects. Interestingly, there is a positive correlation between AGEs levels and insulin resistance.
Conclusions: Circulating levels of AGEs were higher in patients with preeclampsia than those observed in healthy pregnant subjects. Besides, hepatic and metabolic profiles, particularly those related to insulin resistance, were higher in preeclampsia as compared with healthy pregnant subjects. Interestingly, there is a positive correlation between AGEs levels and insulin resistance, suggesting that excessive glycation and an impaired metabolic profile contribute to the physiopathology of preeclampsia.
Export Options
About this article
Cite this article as:
High Plasmatic Levels of Advanced Glycation End Products are Associated with Metabolic Alterations and Insulin Resistance in Preeclamptic Women, Current Molecular Medicine 2020; 20 (9) . https://dx.doi.org/10.2174/1566524020666200220141414
DOI https://dx.doi.org/10.2174/1566524020666200220141414 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Glucocorticoid Receptors and Bone
Current Pharmaceutical Design Human Use of Leucoselect® Phytosome® with Special Reference to Inflammatory- Allergic Pathologies in Frail Elderly Patients
Current Pharmaceutical Design Nuclear Hormone Receptors and Female Reproduction
Current Molecular Medicine New Indications for Established Drugs: Combined Tumor-Stroma-Targeted Cancer Therapy with PPARγ Agonists, COX-2 Inhibitors, mTOR Antagonists and Metronomic Chemotherapy
Current Cancer Drug Targets 2,4-Thiazolidinediones as PTP 1B Inhibitors: A Mini Review (2012-2018)
Mini-Reviews in Medicinal Chemistry Technetium Labeled Small Peptide Radiopharmaceuticals in the Identification of Lung Cancer
Current Pharmaceutical Design Extracellular Matrix in Atherosclerosis: Hyaluronan and Proteoglycans Insights
Current Medicinal Chemistry Peripheral Artery Disease in Diabetes Mellitus: Focus on Novel Treatment Options
Current Pharmaceutical Design Effects of Dietary Non-Fiber Carbohydrates on Composition and Function of Gut Microbiome in Monogastrics: A Review
Protein & Peptide Letters Drug Therapy Aimed at Adenylyl Cyclase to Regulate Cyclic Nucleotide Signaling
Endocrine, Metabolic & Immune Disorders - Drug Targets Mitochondrial Dysfunction during Sepsis
Endocrine, Metabolic & Immune Disorders - Drug Targets The Rise of Carbapenem-Resistant Acinetobacter baumannii
Current Pharmaceutical Design Calcium Channel Blockade and Peroxisome Proliferator Activated Receptor γ Agonism Diminish Cognitive Loss and Preserve Endothelial Function During Diabetes Mellitus
Current Neurovascular Research Redox mechanisms in pathological angiogenesis in the retina: roles for NADPH oxidase
Current Pharmaceutical Design Association of Cytokine Gene Polymorphisms (IL6, IL10, TNF-α, TGF-β and IFN-γ) and Graves’ Disease in Turkish Population
Endocrine, Metabolic & Immune Disorders - Drug Targets Melittin: A Natural Peptide with Expanded Therapeutic Applications
The Natural Products Journal Novel Anti-Cancer Strategy in Bone Tumors by Targeting Molecular and Cellular Modulators of Bone Resorption
Recent Patents on Anti-Cancer Drug Discovery Signal Transduction Therapy of Diabetic Vascular Complication
Current Signal Transduction Therapy Pharmaceutical Nanotechnology United States Patent Watch (April – June 2016)
Pharmaceutical Nanotechnology Editorial [ Are Peptide Therapeutics the Future? Guest Editor: Sivaram Pillarisetti ]
Current Pharmaceutical Biotechnology